Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CANA/MET · 2 trials · 1 indication
Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.
Plasma concentrations of metformin are used to evaluate how long it stays in the body.
Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.
Plasma concentrations of metformin are used to evaluate how long metformin stays in the body.
| Arm | Type | Description |
|---|---|---|
| Canagliflozin/Metformin XR | EXPERIMENTAL | Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg |
| Sequence AB | EXPERIMENTAL | A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B). |
| Sequence BA | EXPERIMENTAL | A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A). |
| Name | Type | Description |
|---|---|---|
| CANA/MET XR FDC | DRUG | Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth) |
Inclusion Criteria: * Must sign an informed consent document indicating they understand the purpose of the study and procedures * Must have a body mass index (BMI) of between 18 and 30 kg/m², inclusive * Must have a body weight of not less than 50 kg * Must have a blood pressure between 90 and 140 ...
CANA/MET is an investigational fixed-dose combination of canagliflozin and metformin, being developed by Johnson & Johnson (JNJ). It is a small molecule studied in healthy volunteers to evaluate the pharmacokinetics of the combination, including multiple-dose exposure and the effect of food on absorption.
CANA/MET is being developed by Johnson & Johnson, traded on the New York Stock Exchange under the ticker JNJ. The company is conducting Phase 1 clinical trials to assess the pharmacokinetics of this fixed-dose combination of canagliflozin and metformin in healthy volunteers.
CANA/MET is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
CANA/MET has completed two Phase 1 trials: NCT02039245, a multiple-dose pharmacokinetic study of canagliflozin/metformin 150/1,000 mg fixed-dose combination, and NCT02039258, a pharmacokinetic study of the combination coadministered with food. Both enrolled healthy volunteers in the United States.
CANA/MET is a fixed-dose combination of canagliflozin and metformin, two established drugs combined into a single tablet. The clinical trials evaluate the pharmacokinetics of this specific combination product, which is distinct from taking the two drugs separately.